2026年3月18日星期三,Compass Pathways(NASDAQ:CMPS)参加了Stifel 2026虚拟中枢神经系统论坛,展示了公司的成就与挑战。该公司分享了COMP360在治疗难治性抑郁症(TRD)方面的积极研究数据,并概述了滚动新药申请(NDA)提交计划。然而,实现商业化准备仍需克服监管障碍。 要点总结 Compass Pathways计划对COMP360进行滚动NDA提交,预计 ...

Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...

Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant ...

Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Analysts are expecting Compass Pathways' stock to blast off soon. There aren't actually any expected near-term events which might drive such a rise. It's fully believable that the company will become ...

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...